Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 304,962	$ 166,130
Restricted cash	0	928
Short-term investments	0	34,651
Prepaid clinical development costs	844	6,081
Inventories	16,136	0
Other prepaid and current assets	23,954	3,924
Total current assets	345,896	211,714
Property and equipment, net	1,276	1,145
Intangible assets	56	56
Total right of use operating lease assets	6,030	1,532
Total assets	353,258	214,447
Current liabilities:
Accounts payable	51,975	28,856
Accrued clinical development costs	7,663	17,511
Other accrued liabilities	24,790	11,871
Revenue interest liability	5,392	5,236
Deferred revenue from collaborations	1,662	2,152
Operating lease liabilities	2,587	454
Total current liabilities	94,069	66,080
Convertible notes, net of issuance costs	179,367	0
Revenue interest liability	171,212	127,308
Operating lease liabilities	3,454	1,109
Other long-term liabilities	1,290	0
Total liabilities	449,392	194,497
Commitments and contingencies (Note 6)
Stockholders’ (deficit) equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of December 31, 2020 and December 31, 2019	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 27,910,366 shares issued at December 31, 2020 and 27,497,911 shares issued and outstanding at December 31, 2019	26	27
Additional paid-in capital	797,655	715,166
Treasury stock, at cost; 1,994,198 shares at December 31, 2020	(54,998)	0
Accumulated other comprehensive gain	0	23
Accumulated deficit	(838,817)	(695,266)
Total stockholders' (deficit) equity	(96,134)	19,950
Total liabilities and stockholders' (deficit) equity	$ 353,258	$ 214,447